Tweaked marrow cells hint at rebuilding brittle bones in osteoporosis

Ten women with advanced osteoporosis received autologous bone-marrow–derived mesenchymal cells engineered to improve bone-homing; after a single infusion, fracture rates dropped dramatically and stayed low for years, suggesting a potential one-time regenerative therapy, though the study was small, lacked a control group, and participants were on standard osteoporosis drugs, requiring larger randomized trials.